ArticleDiabetes, obesity & metabolism2026
Improving cardiovascular risk stratification through the derivation and validation of an elevated triglyceride-glucose index.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Article
- Triglyceride-glucose index as a cardiovascular risk marker: updated evidence, limitations, and future perspectives.Lipids in health and disease · 2026Review
- Comment on Li et al. Association of Triglyceride-Glucose Index and Coronary Chronic Total Occlusion in Patients Undergoing Coronary Angiography: A Retrospective Study.Journal of cardiovascular development and disease · 2026Article
- The association between triglyceride glucose-frailty index and cardiometabolic multimorbidity among Chinese middle-aged and older adults: a national prospective cohort study.Cardiovascular diabetology · 2026Article
- Association between triglyceride-glucose index and vascular dementia in ICU patients with cerebrovascular disease: a retrospective study based on the MIMIC-IV database.BMC neurology · 2026Article
- Improving cardiovascular risk stratification through the derivation and validation of an elevated triglyceride-glucose index.Diabetes, obesity & metabolism · 2026Article
- Association of the C-reactive protein-triglyceride-glucose index with the risk of incident cardiovascular disease in rectal cancer survivors.Frontiers in cardiovascular medicine · 2026Article
- Beyond the triglyceride-glucose index, the cholesterol- high-density lipoprotein -glucose index as a superior predictor for diabetes risk in patients with major adverse cardiovascular events: dual evidence from the CHARLS database and real-world data.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsTriglyceride-glucose (TyG) index, is an emerging prognostic biomarker in atherosclerotic cardiovascular disease (ASCVD). Validation of its clinical value and of clinically relevant prognostic cut-off, remains an unmet need to integrate TyG into primary prevention protocols.
methodsTo assess the clinical applicability of TyG, a composite of cardiovascular mortality, myocardial infarction, coronary revascularization or stroke was used as the primary endpoint in a general population cohort (ATTICA cohort, n = 1677, derivation cohort). Next, we derived an optimal prognostic TyG cut-off and externally validated it in a primary prevention cohort (n = 1237). To assess the clinical value of TyG, we analysed 1170 consecutively recruited patients from an ongoing registry aiming to stratify ASCVD risk (Athens Cardiometabolic Cohort) and assessed indices of subclinical arterial injury and progression of atherosclerosis. The TyG index was calculated by the formula: ln[fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2].
resultsTyG index was independently associated with increased CVD events in the derivation cohort (HR = 1.33, p = 0.020). The incremental value of a derived optimal cut-off of 8.46 over SCORE2 was confirmed in both derivation and validation cohorts [net reclassification index (NRI) = 0.668 and 0.469 respectively, Delta Harrell's C index = 0.054 and 0.044 respectively, p < 0.05 for all]. Elevated TyG index was associated with more diseased vascular beds (OR = 2.00, 95% CI 1.24-3.24), progression of subclinical carotid atherosclerosis (OR = 2.99, 95% CI 1.10-8.17) at follow-up and established ASCVD (p < 0.05 for all).
conclusionsTyG is associated with increased prevalence and progression of subclinical and clinically overt ASCVD. In individuals assessed for primary prevention a TyG≥8.46 may serve as a risk enhancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.